TY - JOUR T1 - Breathomics for the clinician: the use of volatile organic compounds in respiratory diseases JF - Thorax JO - Thorax SP - 514 LP - 521 DO - 10.1136/thoraxjnl-2020-215667 VL - 76 IS - 5 AU - Wadah Ibrahim AU - Liesl Carr AU - Rebecca Cordell AU - Michael J Wilde AU - Dahlia Salman AU - Paul S Monks AU - Paul Thomas AU - Chris E Brightling AU - Salman Siddiqui AU - Neil J Greening Y1 - 2021/05/01 UR - http://thorax.bmj.com/content/76/5/514.abstract N2 - Exhaled breath analysis has the potential to provide valuable insight on the status of various metabolic pathways taking place in the lungs locally and other vital organs, via systemic circulation. For years, volatile organic compounds (VOCs) have been proposed as feasible alternative diagnostic and prognostic biomarkers for different respiratory pathologies.We reviewed the currently published literature on the discovery of exhaled breath VOCs and their utilisation in various respiratory diseasesKey barriers in the development of clinical breath tests include the lack of unified consensus for breath collection and analysis and the complexity of understanding the relationship between the exhaled VOCs and the underlying metabolic pathways. We present a comprehensive overview, in light of published literature and our experience from coordinating a national breathomics centre, of the progress made to date and some of the key challenges in the field and ways to overcome them. We particularly focus on the relevance of breathomics to clinicians and the valuable insights it adds to diagnostics and disease monitoring.Breathomics holds great promise and our findings merit further large-scale multicentre diagnostic studies using standardised protocols to help position this novel technology at the centre of respiratory disease diagnostics. ER -